| DOI | Trouver le DOI : https://doi.org/10.1016/j.vaccine.2012.11.067 |
|---|
| Auteur | Rechercher : Gerdts, V.; Rechercher : Mutwiri, G.; Rechercher : Richards, J.1; Rechercher : Hurk, S.V.D.L.V.D.; Rechercher : Potter, A.A. |
|---|
| Affiliation | - Conseil national de recherches du Canada
|
|---|
| Format | Texte, Article |
|---|
| Sujet | alginic acid; chitosan; CpG oligodeoxynucleotide; DNA vaccine; drug carrier; gamma interferon; glycoconjugate; glycoconjugate vaccine; Haemophilus vaccine; hepatitis B surface antigen; immunoglobulin A; immunoglobulin G1; immunoglobulin G2; immunoglobulin M; immunostimulating agent; influenza vaccine; interleukin 2; interleukin 6; liposome; nanoparticle; peptide vaccine; poly[di(sodium carboxylatoethylphenoxy] phosphazene; poly[di(sodium carboxylatophenoxy)] polyphosphazene; polyglactin; polymer; polysaccharide vaccine; starch; unclassified drug; vaccine; Wart virus vaccine; Actinobacillus pleuropneumoniae; antigen presenting cell; atrophic rhinitis; bacterial load; Bordetella bronchiseptica; bronchopneumonia; CD8+ T lymphocyte; cost effectiveness analysis; cytokine production; cytotoxic T lymphocyte; dendritic cell; Haemophilus influenzae type b; Human papillomavirus type 16; immunization; immunogenicity; mucosal immunity; Neisseria meningitidis; Pasteurella multocida infection; review; Streptococcus pneumoniae; virus like agent; Glycoconjugates; Nanoparticles; Vaccination; Vaccines; Vaccines, Conjugate; Vaccines, Subunit; Vaccines, Virus-Like Particle |
|---|
| Résumé | The practice of immunization of animals and humans has been carried out for centuries and is generally accepted as the most cost effective and sustainable method of infectious disease control. Over the past 20 years there have been significant changes in our ability to produce antigens by conventional extraction and purification, recombinant DNA and synthesis. However, many of these products need to be combined with carrier molecules to generate optimal immune responses. This review covers selected topics in the development of carrier technologies for use in the veterinary vaccine field, including glycoconjugate and peptide vaccines, microparticle and nanoparticle formulations, and finally virus-like particles. © 2012. |
|---|
| Date de publication | 2013 |
|---|
| Dans | |
|---|
| Langue | anglais |
|---|
| Publications évaluées par des pairs | Oui |
|---|
| Numéro NPARC | 21270587 |
|---|
| Exporter la notice | Exporter en format RIS |
|---|
| Signaler une correction | Signaler une correction (s'ouvre dans un nouvel onglet) |
|---|
| Identificateur de l’enregistrement | ae945c23-371e-467a-a9fd-4b5aa6ba079d |
|---|
| Enregistrement créé | 2014-02-17 |
|---|
| Enregistrement modifié | 2020-04-22 |
|---|
